Medica in Germany revealed the extend of new diagnostic systems in the industry, the readiness of the majors to renew their pipeline and the necessity for a cheap innovative technology which elevates immunoassays' accuracy into levels of molecular sensitivity.
The competition is fierce between the leaders and our glue is a hot topic between the companies. We could not be better positioned as our technology has proven its sensitivity and scalability above peer innovations.
The recent patent approval paved the way for legal steps in our negotiations and it appears that our patience will be rewarded soon.
In my humble opinion, this is the start of the run towards the announcement containing an additional signature.
In previous posts I had speculated that Roche would indeed be a prime candidate to be this IVD major and Medica only supported the likelihood of that assumption further.
ADO Price at posting:
7.2¢ Sentiment: Buy Disclosure: Held
